Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn about a recent article by Fabian Müller et al, published in New England Journal of Medicine:
“Groundbreaking in UC!
For the first time, CAR T-cell therapy — originally built for lymphoma and now used in lupus and systemic sclerosis — has shown success in ulcerative colitis (UC).
Case details:
21-year-old with severe, multidrug-resistant UC (failed steroids, biologics, JAK inhibitors, cyclosporine, and more).
Received CD19 CAR T-cell therapy after multiple failed options including blinatumomab.
Achieved complete clinical, biochemical, and mucosal remission within 14 weeks.
Gained 20 lbs and resumed normal life.
Only mild side effects (grade 1 CRS, neutropenia).
Why this matters:
UC has never been considered a B-cell–driven disease, making this remission unexpected. If replicated, CAR T may expand its reach far beyond current autoimmune indications.
Caveat: Just 1 patient, short follow-up (14 weeks). Larger trials needed.
Still — a major step that could reshape UC treatment in the future.”
Title: CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis
Authors: Fabian Müller, Raja Atreya, Simon Völkl, Michael Aigner, Sascha Kretschmann, Soraya Kharboutli, Moritz Leppkes, Selina Sitte, Deike Strobel, Arndt Hartmann, Saurabh Mehandru, Jean-Frederic Colombel, Georg Schett, Andreas Mackensen, Markus F Neurath
Read the Full Article on New England Journal of Medicine
More posts featuring Yan Leyfman.